EcoDrugPlus

Integrin, Alpha 5 (Fibronectin Receptor, Alpha Polypeptide)

Ensembl ID : ENSOMYG00000023559
Gene Symbol: ITGA5
1 Cross references
200 Possible Orthologues:

Integrin, Alpha 5 (Fibronectin Receptor, Alpha Polypeptide)

Ensembl ID : ENSOMYG00000025626
Gene Symbol: ITGA5
2 Cross references
200 Possible Orthologues:

Integrin, Alpha V

Ensembl ID : ENSOMYG00000072888
Gene Symbol: ITGAV
1 Cross references
230 Possible Orthologues:

Integrin, Beta 1a

Ensembl ID : ENSOMYG00000035502
Gene Symbol: ITGB1A
1 Cross references
209 Possible Orthologues:

Integrin, Beta 1a

Ensembl ID : ENSOMYG00000040711
Gene Symbol: ITGB1A
1 Cross references
209 Possible Orthologues:

Integrin, Beta 5

Ensembl ID : ENSOMYG00000000428
Gene Symbol: ITGB5
1 Cross references
204 Possible Orthologues:

Integrin, Beta 5

Ensembl ID : ENSOMYG00000044820
Gene Symbol: ITGB5
1 Cross references
204 Possible Orthologues:

Integrin, Beta 7

Ensembl ID : ENSOMYG00000016437
Gene Symbol: ITGB7
1 Cross references
144 Possible Orthologues:

Interleukin-1 Receptor-Associated Kinase 4

Ensembl ID : ENSOMYG00000030965
Gene Symbol: IRAK4
1 Cross references
200 Possible Orthologues:

Isocitrate Dehydrogenase (Nadp(+)) 1

Ensembl ID : ENSOMYG00000022000
Gene Symbol: IDH1
1 Cross references
228 Possible Orthologues:

Isocitrate Dehydrogenase (Nadp(+)) 1

Ensembl ID : ENSOMYG00000015786
Gene Symbol: IDH1
1 Cross references
227 Possible Orthologues:

Isocitrate Dehydrogenase (Nadp(+)) 2

Ensembl ID : ENSOMYG00000032833
Gene Symbol: IDH2
2 Cross references
200 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).